Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF1K16 plus bevacizumab in recurrent or progressive brain glioma (Phase II, China)
ChiCTR2600126789Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of HF1K16 in cerebral glioma and glioma (3 arms), sponsored by Huashan Hospital. Primary endpoints: Safety, Tolerability and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HF1K16
03
Conditions
cerebral gliomaglioma
Beyond the preview
Go deeper on ChiCTR2600126789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126789.